CagriSema and EloraTZP are experimental combinations that pair amylin-pathway medicines with incretin drugs, but they are at different stages of development and their results cannot be compared as if they came from one trial. Novo Nordisk has reported Phase 3 CagriSema results and said it submitted a U.S. FDA application for weight management in December 2025. Eli Lilly’s EloraTZP combination has reported Phase 2b results; Lilly said it planned to start Phase 3 studies in the fourth quarter of 2026. The early evidence makes both approaches worth watching, but it does not establish which combination is more effective or safer.
What are CagriSema and EloraTZP?
Both candidates combine an amylin-pathway medicine with a drug that acts on incretin hormone receptors. Their ingredients, targets, and trial formats differ.
CagriSema: cagrilintide plus semaglutide
CagriSema is Novo Nordisk’s fixed-dose, once-weekly injectable combination of cagrilintide and semaglutide. In the pivotal regimen described by the company, each medicine is dosed at 2.4 mg. Cagrilintide is a long-acting amylin analogue; semaglutide is a GLP-1 receptor agonist. Novo said its December 2025 U.S. FDA application sought a weight-management indication alongside reduced-calorie eating and increased physical activity. At that time, Novo said CagriSema was not approved in the United States or European Union.
EloraTZP: eloralintide plus tirzepatide
EloraTZP is Lilly’s investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, which activates both GIP and GLP-1 receptors. Lilly describes the combination as targeting three complementary nutrient-stimulated hormone pathways: amylin, GIP, and GLP-1. In the reported 48-week Phase 2b study, the medicines were given as separate injections. Lilly said it would advance a co-formulation into Phase 3.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
How do their clinical results compare?
The table puts the reported evidence side by side for orientation, not as a direct efficacy ranking. The trials differ in population, duration, dose, comparator, and statistical analysis; a percentage from one study cannot be treated as the result of a head-to-head test against the other drug.
| Comparison point | CagriSema | EloraTZP |
|---|---|---|
| Developer and ingredients | Novo Nordisk; cagrilintide plus semaglutide. | Eli Lilly; eloralintide plus tirzepatide. |
| Hormone targets | Amylin pathway and GLP-1 receptor. | Amylin receptor, GIP receptor, and GLP-1 receptor. |
| Combination format | Fixed-dose, once-weekly injectable combination in the pivotal regimen reported by Novo. | Separate injections in the reported Phase 2b study; Lilly said a co-formulation would advance into Phase 3. |
| Development and regulatory stage | Phase 3 results reported; Novo said it submitted a U.S. FDA weight-management application in December 2025. The review outcome as of October 3, 2026, is not established by the cited company announcements. | Combination results reported from Phase 2b; Lilly said it planned to begin Phase 3 studies in Q4 2026. |
| Key weight-loss study population | REDEFINE 1 enrolled adults with obesity or overweight plus a weight-related complication, without diabetes. | The 48-week Phase 2b study enrolled 367 adults with obesity or overweight and type 2 diabetes. |
| Duration and comparator | REDEFINE 1: 68 weeks; placebo comparator. A separate REDEFINE 4 trial compared CagriSema with tirzepatide for 84 weeks. | Phase 2b: 48 weeks; the highest-dose combination was compared with tirzepatide 15 mg alone, among other study arms. |
| Dose and reported weight-loss result | REDEFINE 1: the reported pivotal regimen was cagrilintide 2.4 mg plus semaglutide 2.4 mg. Novo reported 22.7% weight loss at 68 weeks under the trial-product estimand and 20.4% under the treatment-policy estimand. | Phase 2b: the highest-dose combination listed was eloralintide 9 mg plus tirzepatide 15 mg. Lilly reported 23.3% weight loss at 48 weeks under its efficacy estimand. |
| How the result was analyzed | Trial-product estimand assumes participants stayed on treatment and took no other weight-loss therapies. Treatment-policy estimand evaluates the treatment effect regardless of whether participants remained on treatment. These are different estimates. | The 23.3% figure was reported under the study’s efficacy estimand. It is not the same trial or analysis as either REDEFINE 1 estimate. |
| A1C result | Not stated for the cited REDEFINE 1 result (Novo Nordisk). | Lilly reported a 2.9 percentage-point A1C reduction at 48 weeks in the highest-dose combination arm; tirzepatide 15 mg alone showed a 2.4 percentage-point reduction in this study. |
| Gastrointestinal events and discontinuations | In REDEFINE 1, Novo reported nausea in 55.0% of CagriSema participants versus 12.6% with placebo, constipation in 30.7% versus 11.6%, and vomiting in 26.1% versus 4.1%. Adverse-event discontinuation was 5.9% versus 3.5%. | Lilly said gastrointestinal events were most common, generally mild or moderate, and occurred primarily during dose escalation. Adverse-event discontinuation ranged from 10.8% to 27.0% across combination arms. |
These are results from different programs and are not a head-to-head comparison of CagriSema with EloraTZP. In particular, CagriSema’s 22.7% REDEFINE 1 estimate is from a 68-week study in participants without diabetes and uses the trial-product estimand; EloraTZP’s 23.3% is from a 48-week Phase 2b study in participants with type 2 diabetes and uses the study’s efficacy estimand. Differences in population, treatment duration, doses, comparator, and analysis prevent a meaningful ranking from those two percentages alone.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
What does CagriSema’s direct comparison with tirzepatide show?
There is a relevant head-to-head result for CagriSema, but its comparator was tirzepatide alone—not EloraTZP. In the open-label Phase 3 REDEFINE 4 trial, 809 people with obesity and at least one comorbidity were treated for 84 weeks. Novo reported weight loss of 23.0% with CagriSema 2.4 mg/2.4 mg and 25.5% with tirzepatide 15 mg under the protocol efficacy estimand. Under the treatment-regimen estimand, the respective results were 20.2% and 23.6%. CagriSema did not meet the trial’s primary endpoint of non-inferiority to tirzepatide. The open-label design and the doses tested are important context; the trial does not answer how CagriSema compares with Lilly’s EloraTZP combination.
Novo also announced topline results from Phase 3 REIMAGINE 5 and REDEFINE 9 on September 21, 2026, describing superior weight loss for CagriSema 1.0 mg/1.0 mg versus tirzepatide 5 mg. The announcement excerpt does not provide enough detail to characterize the trial populations, estimands, or statistics. That topline claim should therefore be limited to the lower-dose comparison Novo described, rather than generalized to other doses or settings.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
What do the findings suggest—and what can’t they prove?
The results suggest that combining amylin-pathway treatment with incretin medicines may produce substantial weight loss, and Lilly’s Phase 2b result also includes a substantial A1C reduction in a population with type 2 diabetes. That is a rationale for continued clinical development, not proof that either candidate will become a better treatment than currently available options.
- There is no CagriSema-versus-EloraTZP trial in the cited evidence. A fair comparison would require a randomized study with comparable populations, doses, follow-up, endpoints, and analysis methods.
- Study phase matters. CagriSema has Phase 3 results and a reported U.S. application submission; EloraTZP’s combination evidence is Phase 2b, with Phase 3 planned for Q4 2026.
- Results in people with and without diabetes are not interchangeable. REDEFINE 1 excluded people with diabetes, whereas the EloraTZP Phase 2b study enrolled participants with type 2 diabetes.
- Weight-loss estimates depend on the analysis method. REDEFINE 1’s trial-product and treatment-policy estimates answer different questions, so the estimand must accompany the quoted percentage.
What is known about tolerability?
Both developers reported gastrointestinal effects as a prominent tolerability issue, but adverse-event rates from separate trials should not be used to rank one combination against the other. Trial populations, designs, dose escalation, exposure, and reporting conditions differ.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
For EloraTZP, Lilly said gastrointestinal events were more frequent in combination arms than with eloralintide or tirzepatide alone. Its reported adverse-event discontinuation rates were 10.8% to 27.0% across EloraTZP arms, compared with 0% to 10.8% for eloralintide, 2.9% for tirzepatide, and 16.7% for placebo. These Phase 2b figures are specific to that trial; they do not establish how tolerability would compare with CagriSema in a shared study.
Are either of these drugs available for routine treatment?
The cited announcements do not establish approval or routine availability for either combination. Novo said it submitted a U.S. FDA application for CagriSema in December 2025, but the review outcome as of October 3, 2026, is not established in the cited sources. Lilly’s combination evidence is from Phase 2b, and its planned Phase 3 start does not amount to an approval. Eventual labels, availability, prices, and real-world roles cannot be concluded from these trial announcements.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Quick Recap
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
